Featured Articles
(Yahoo! Finance) Sept 21, 2017 - AstraZeneca Canada is pleased to announce that the pan-Canadian Oncology Drug Review (pCODR) has provided an overwhelmingly positive clinical recommendation for the reimbursement of Lynparza® (olaparib), a first-of-its-kind treatment for BRCA-mutated ovarian cancer.
Read Article
(Business Insider) Sept 20, 2017 - Johnson & Johnson continues to face a growing number of product liability claims over the alleged association between its talcum powder products and ovarian cancer. According to an update provided by the U.S. Judicial Panel on Multidistrict Litigation (JPML) on September 15th, there are at least 878...
Read Article
Latest Articles
September 19, 2017
September 15, 2017
September 14, 2017
September 13, 2017
September 11, 2017
September 08, 2017
September 08, 2017
September 06, 2017
View More
News Commentary
There is no Ovarian commentary.

OBR Green
There are no Ovarian OBR Green articles.
Featured Videos
There are no videos.
OBR Blog
There are no Ovarian blog entries.